TG Therapeutics Inc. (TGTX) Has Soared To A New High On Phase 3 Study Results

TG Therapeutics Inc. (TGTX) announced Monday morning that its Phase 3 trial of TG-1101 plus ibrutinib in patients with previously treated high risk Chronic Lymphocytic Leukemia met its primary endpoint.

from RTT - Hot Stocks http://ift.tt/2mwbFdf
via IFTTT